Enfusion Inc

Enfusion — Q4 2022 Earnings Presentation

21 slides from Enfusion's earnings presentation, Mar 7, 2023

  1. Slide 1: Enfusion 4Q 2022 Shareholder Letter March 2023

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 4Q 2022 Shareholder Letter March 2023

  2. Slide 2: Disclaimer: Forward-Looking Statements

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (Se

  3. Slide 3: Dear Shareholders

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, Enfusion ended 2022 – its first full calendar year after the IPO - on a high note. During volatile market conditions, the resiliency of our business tends to shine and accentuate the value we provide to our client

  4. Slide 4: Our mission

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. To help solve investment managers’ evolving business and operational challenges through next generation technology Our mission 4

  5. Slide 5: We simplify and unify the investment management lifecycle

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. …empowering teams to operate in concert CFO COO CIO Portfolio Manager Analysts Traders Compliance Officer Investor Relations Middle Office Back Office We simplify and unify the investment management lifecycle We manage complex workflo

  6. Slide 6: Serving clients across the investment management industry

    6 Serving clients across the investment management industry Alternative Investment Managers Hedge Funds Private Equity Private Credit Family Offices Institutional Investment Managers Wealth Managers Traditional Asset Managers Mutual Funds Sovereign Wealth Funds

  7. Slide 7: Purpose-built end-to-end solution

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Purpose-built end-to-end solution 7 Portfolio Management System Order Execution Management System Technology-Powered Services Accounting / General Ledger Analytics • Live details of portfolio positions • Real-time Investment Book of R

  8. Slide 8: Addressing a large and growing market

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Robust growth in Underlying industry Addressing a large and growing market $11.5bn $5.7bn $2.0bn $19bn+ Software & IT services from Investment Management Internal IT spend IT hardware spend Source: IDC’s Worldwide Capital Markets IT S

  9. Slide 9: Client-centric approach: Why we win

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 9 Client-centric approach Why we win One end-to-end solution, one single dataset and source of truth Rapid pace of delivery and evolution Open, flexible and tailored Unique ability to lead with a single solution – and then adjust to a

  10. Slide 10: Q4 2022 key financial highlights

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Q4 2022 key financial highlights $40.5 27.2% YoY Growth Adjusted Free Cash Flow Z00 Total Revenue Z00 Adjusted EBITDA Z00 53.4% FCF Conversion $3.6 $27.2 67.2% Highly attractive SaaS model with combination of scale, growth and profita

  11. Slide 11: Strong growth trends with expanding profitability

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $3.2 $1.8 $5.3 $5.4 $6.8 $2.6 $0.8 4Q21 1Q22 2Q22 3Q22 4Q22 Adjusted EBITDA Net Income Strong growth trends with expanding profitability Operating Cash Flow and Adjusted Free Cash Flow $ in millions $31.9 $34.1 $36.5 $39.2 $40.5 4Q21

  12. Slide 12: Organic, sticky expansion at scale

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $127.1 $137.6 $148.7 $158.7 $164.7 4Q21 1Q22 2Q22 3Q22 4Q22 115.0% 115.8% 121.9% 116.6% 115.4% 4Q21 1Q22 2Q22 3Q22 4Q22 Organic, sticky expansion at scale 12 Net Dollar Retention Rate(1) Avg Contract Value 734 756 793 810 819 4Q21 1Q2

  13. Slide 13: Financial outlook 2023E

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Financial outlook 13 2023E Revenue $185 $190 million ̶ Adjusted EBITDA $32 ̶ $34 million *Adjusted EBITDA guidance excludes stock-based compensation of $12 million for the full year 2023. These statements are forward-looking and actua

  14. Slide 14: Appendix

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Appendix

  15. Slide 15: Consolidated Balance Sheets

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 15 ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars in thousands, except shares and unit amounts and par value) (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 62,545 $ 64,365 Accounts receivable, net 25,855 18,223 P

  16. Slide 16: Consolidated Statements of Operations

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 16 ENFUSION. INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars in thousands) (Unaudited) 2022 2021 REVENUES: Plat form subscriptions $ 29,562 37,804 $ 138,868 $ 103,259 Managed services 1,979 2,691 9,821 7,119 Other 312 22 1,660 1,3

  17. Slide 17: Consolidated Statements of Cash Flows

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 17 ENFUSION. INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (Unaudited) Cash flows from operating activities: Net (loss) income $ (13,263) $ (282,242) Adjustments to reconcile net (loss) income to net cash provided

  18. Slide 18: Reconciliations to Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 18 The following table reconciles net income to Adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: ($ in thousands) December 31, 2021 March 30, 2022 Ju

  19. Slide 19: Reconciliations of Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations of Non-GAAP Financial Measures 19 The following table reconciles operating cash flow to unlevered free cash flow and adjusted free cash flow: The Company’s stock compensation expense was recognized in the following cap

  20. Slide 20: Definitions: Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 20 Definitions Non-GAAP Financial Measures In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjus

  21. Slide 21: Definitions Continued: Key Metrics

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 21 Definitions Continued Key Metrics: In connection with the management of our business, we identify, measure and assess a variety of key metrics. The key metrics we use in managing our business are set forth below. Annual Recurring R

Enfusion — Q4 2022 Earnings Presentation on 6ix